Tofacitinib and newer JAK inhibitors in inflammatory bowel disease – where we are and where we are going

Eleanor Liu, Nasar Aslam, Gaurav Nigam, Jimmy K Limdi

Article Type



This narrative review summarizes the current literature regarding the mechanism of action of tofacitinib, data from registrational trials, emerging real-world evidence, and an overview of the most recent safety evidence. The authors explore evolving treatment paradigms and also present a brief overview of the next generation of JAK inhibitors in the pipeline.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.